{"name":"Axovant Sciences Ltd.","slug":"axovant-sciences-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":53399000,"netIncome":-71887000,"cash":63729000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"RVT-101","genericName":"RVT-101","slug":"rvt-101","indication":"Alzheimer's disease","status":"phase_3"}]}],"pipeline":[{"name":"RVT-101","genericName":"RVT-101","slug":"rvt-101","phase":"phase_3","mechanism":"RVT-101 is a small molecule that targets the tau protein to treat neurodegenerative diseases.","indications":["Alzheimer's disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxORV9rNzJNLWJ2WWxXTktiM05GaUE3a3k2Z3dub2hlREZWUGdvVDBNT05Xbmh2U1lUWmFfMzFHaHhJY1Rhb2FmNWx6M3hwNW54YXQxeEZ3UFE1U1AyNy1JUVM4TTVLYVdEdGpkenJpaUZ1a2tyLUh6LWhMRGJjZVF5LUtVWmRPVTBVaXNKNXpTU2dNck5OaE1raVRYd1dwUXh4alRsemtURkZJc0VlUE1SdmpSYVpsZE16eXFuV3llaURzSVJ3MUtRYy1yYWFEaFJKZG42YndSbmhOV0U?oc=5","date":"2025-04-22","type":"pipeline","source":"PR Newswire","summary":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight - PR Newswire","headline":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOR0pBa1JhZUtpQ1FqZ0g3ZFdvSWpiNjlPemlZQmR5Qk1ENVdxR29lT0Exek5taGdGeUp4ZXZJTEJ1N3QxTzV3b0ZmeWFnN1pXTGlacGY5QXBRcm9GLWY3LXZ3VjFDb1pMajdLT1FnU1ltRGllWGZfbDFHaFdGTWt3Sld2U1k?oc=5","date":"2023-09-01","type":"pipeline","source":"Newsweek","summary":"Vivek Ramaswamy Is a Fraud—and Always Has Been | Opinion - Newsweek","headline":"Vivek Ramaswamy Is a Fraud—and Always Has Been | Opinion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPZ3hpOUx1c0lFbTlvNXRuS2NRMEhBR2lBMV9wVjN3NzQydlVxdVJYaGJEcTZmRjJoLVhzYnpsMklqLXZzYmlneXFubUdKczA2WHhNQUVSTnVvMFhodHBsMmxTNl9WWjdlSFlTdUNfUmNyUDh2Rko3eUp3U1lIWUtoZWh3ZnJEaTA?oc=5","date":"2023-05-14","type":"pipeline","source":"Politico","summary":"How Vivek Ramaswamy made a fortune before pivoting to politics - Politico","headline":"How Vivek Ramaswamy made a fortune before pivoting to politics","sentiment":"neutral"},{"date":"2023-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-03-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-02-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2023-02-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-02-10","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC: SC 13G","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2022-12-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2022-11-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2022-11-10","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE4wMWMyM1M4NGMxN2FPX0dSM0lVMGFjNjBoVFpRTmQwOTR2RkluLU41UTBxRTAyZTYtUlF4eHdtMk95bFN5WTRWVzVaYUdrblV5a1RwQmxtSHUwUExGc2J0M0hkLTZCaWhvLV9jUEVKVUszRTlfWUpyN0s3bw?oc=5","date":"2022-06-22","type":"pipeline","source":"Labiotech.eu","summary":"Biotech from the Bermuda Islands Brings Good News for Dementia Patients - Labiotech.eu","headline":"Biotech from the Bermuda Islands Brings Good News for Dementia Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOVzdfMHBKbUozV1llcnZMWEozUVkxcnVEN29aNTVUcmlrWmtvTk9HanJ4V2IyWVQzUXZ2cVZtN2xqWElxb3A0QlhDMUR0RVZOdnl2QlZvejNxYnJER0szaVNLTFJvRWtaakZvZ2pqZ0ZZRUY4TWxQOTdiZTZxSjdhdTQ4NzZhY2s?oc=5","date":"2022-04-28","type":"pipeline","source":"BioPharma Dive","summary":"After setbacks, a gene therapy company mulls a sale - BioPharma Dive","headline":"After setbacks, a gene therapy company mulls a sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxQRFF5MWRsSUZaRm1GaEVQMTdHaTYwOTViUk9ya3YwVlhoLV8ybUJqLTZURS01UWlMZlVCNEJoOHZ2bVpra1pFdUNiZ1NjNmZJenJqeWVOSzZxY0EtcFZWV1lSM25OLXhwdHBVVWNaZTBUVVEwNXBBb2NvU2hOMkctSkc5VmZFTzlMMlE?oc=5","date":"2018-12-10","type":"trial","source":"BioSpace","summary":"Axovant Abandons Another Dementia Drug After Failed Trial - BioSpace","headline":"Axovant Abandons Another Dementia Drug After Failed Trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQV0hhZkVhd215bExpeTNpYmtJdkQ0dzE5YnlnRmJ6Qmk3ZWRRdF9MYk5oVkxSaWFESFl2M2tfWTVsWGdKMjlUOE5lcWdodzFKSzBXc0p4bFVrV3RkZnlmZ2padW1heWU2YWdoUnFiUFlaRUk3LTlHY3NBUkJXdHRQdXRMQ2VkaTNMVVpqVXozVHhFS0pIaTgtS2RoV2xTNDFPMExmV0s4RmIwY001X3FGWGlVV0I?oc=5","date":"2018-03-01","type":"pipeline","source":"Bloomberg.com","summary":"Casino-Backed Startup Eyes Alzheimer's Cure Worth $2.5 Billion - Bloomberg.com","headline":"Casino-Backed Startup Eyes Alzheimer's Cure Worth $2.5 Billion","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":53399000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-71887000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":63729000,"cashHistory":[],"totalAssets":75080000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}